Literature DB >> 27563537

Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Massimo De Paschale1, Pierangelo Clerici1.   

Abstract

Varicella-zoster virus, which is responsible for varicella (chickenpox) and herpes zoster (shingles), is ubiquitous and causes an acute infection among children, especially those aged less than six years. As 90% of adults have had varicella in childhood, it is unusual to encounter an infected pregnant woman but, if the disease does appear, it can lead to complications for both the mother and fetus or newborn. The major maternal complications include pneumonia, which can lead to death if not treated. If the virus passes to the fetus, congenital varicella syndrome, neonatal varicella (particularly serious if maternal rash appears in the days immediately before or after childbirth) or herpes zoster in the early years of life may occur depending on the time of infection. A Microbiology laboratory can help in the diagnosis and management of mother-child infection at four main times: (1) when a pregnant woman has been exposed to varicella or herpes zoster, a prompt search for specific antibodies can determine whether she is susceptible to, or protected against infection; (2) when a pregnant woman develops clinical symptoms consistent with varicella, the diagnosis is usually clinical, but a laboratory can be crucial if the symptoms are doubtful or otherwise unclear (atypical patterns in immunocompromised subjects, patients with post-vaccination varicella, or subjects who have received immunoglobulins), or if there is a need for a differential diagnosis between varicella and other types of dermatoses with vesicle formation; (3) when a prenatal diagnosis of uterine infection is required in order to detect cases of congenital varicella syndrome after the onset of varicella in the mother; and (4) when the baby is born and it is necessary to confirm a diagnosis of varicella (and its complications), make a differential diagnosis between varicella and other diseases with similar symptoms, or confirm a causal relationship between maternal varicella and malformations in a newborn.

Entities:  

Keywords:  Congenital varicella syndrome; Microbiology laboratory; Mother-child infection; Neonatal varicella; Varicella-zoster virus

Year:  2016        PMID: 27563537      PMCID: PMC4981827          DOI: 10.5501/wjv.v5.i3.97

Source DB:  PubMed          Journal:  World J Virol        ISSN: 2220-3249


  470 in total

1.  Susceptibility to varicella-zoster among pregnant women in the province of Lecce, Italy.

Authors:  M Guido; A Tinelli; A De Donno; M Quattrocchi; A Malvasi; F Campilongo; A Zizza
Journal:  J Clin Virol       Date:  2011-11-09       Impact factor: 3.168

2.  Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother.

Authors:  M B Salzman; R G Sharrar; S Steinberg; P LaRussa
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

3.  A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades.

Authors:  Geoffrey A Peters; Shaun D Tyler; Charles Grose; Alberto Severini; Michael J Gray; Chris Upton; Graham A Tipples
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Impaired antibody memory to varicella zoster virus in HIV-infected children: low antibody levels and avidity*.

Authors:  A G L'Huillier; T Ferry; D S Courvoisier; C Aebi; J-J Cheseaux; C Kind; C Rudin; D Nadal; B Hirschel; C Sottas; C-A Siegrist; K M Posfay-Barbe
Journal:  HIV Med       Date:  2011-07-03       Impact factor: 3.180

Review 5.  Management of varicella infection (chickenpox) in pregnancy.

Authors:  Alon Shrim; Gideon Koren; Mark H Yudin; Dan Farine
Journal:  J Obstet Gynaecol Can       Date:  2012-03

6.  Congenital varicella-zoster virus infection. A rare case of severe brain and ocular malformations without limb or cutaneous involvement in a newborn after maternal subclinical infection.

Authors:  Yousef A Al-Katawee; Yousef A Al-Hasoun; Mohamed N Taha; Khalid Al-Moslem
Journal:  Saudi Med J       Date:  2005-05       Impact factor: 1.484

Review 7.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

8.  Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella.

Authors:  S Suga; T Yoshikawa; T Ozaki; Y Asano
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

9.  Measurement of antibodies to varicella-zoster virus using a virus-free fluorescent-antibody-to-membrane-antigen (FAMA) test.

Authors:  Rackhyun Park; Ji Young Hwang; Kang Il Lee; Sim Namkoong; Seuk-Keun Choi; Songyong Park; Hosun Park; Junsoo Park
Journal:  J Microbiol Biotechnol       Date:  2015-02       Impact factor: 2.351

10.  Seroprevalence of varicella-zoster virus and predictors for seronegativity in the Amsterdam adult population.

Authors:  Gini G C van Rijckevorsel; Marjolein Damen; Gerard J Sonder; Maarten F Schim van der Loeff; Anneke van den Hoek
Journal:  BMC Infect Dis       Date:  2012-06-21       Impact factor: 3.090

View more
  3 in total

1.  Uptrend prevalence of varicella parallel with low serum antibodies and low second-dose rate among children 10-14 years old in Wenzhou, China.

Authors:  Qi Liu; Jiake Yu; Jingjiao Wei; Hu Zhang; Jie Jin; Weikun Zheng; Yufei Ruan; Jinsheng Yu; Yiping Chen
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

Review 2.  Pregnancy and infection: using disease pathogenesis to inform vaccine strategy.

Authors:  Meghan S Vermillion; Sabra L Klein
Journal:  NPJ Vaccines       Date:  2018-02-01       Impact factor: 7.344

Review 3.  Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature.

Authors:  Lei Wang; Erik A M Verschuuren; Coretta C van Leer-Buter; Stephan J L Bakker; Anoek A E de Joode; Johanna Westra; Nicolaas A Bos
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.